Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care. Ursula A. Matulonis, MD, surveyed the exploitable genetic ...
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic ...
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients ...
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer. Leah Katz, MD, MPH, discusses long-term IDEA trial data ...
Certainly also drugs that interact with DNA damage and repair. PARP inhibitors have a very fixed now role in how we take care ...
“Blinatumomab is excellent at eradicating MRD in a [patient with] MRD-positive [disease], regardless of which ALL it is, ...
Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a ...
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in ...
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and ...
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care. Andrew Pecora, MD, has never been the kind of physician ...
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results